TauRx raises $135M in equity financing

TauRx Pharmaceuticals Ltd. (Singapore) said it received the final tranche of a $135 million equity financing that began in March. Executive Chairman Claude Wischik declined to name its investors, but said most were new investors.

TauRx expects data next year from two Phase III trials of lead candidate LMTX to treat Alzheimer's disease and one to treat frontotemporal dementia. The second generation tau aggregation inhibitor is a modified form of rember methylthioninium chloride (methylene blue). ...